Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination

BACKGROUND: Limited response to programmed death ligand-1 (PD-L1)/programmed death 1 (PD-1) immunotherapy is a major hindrance of checkpoint immunotherapy in non-small cell lung cancer (NSCLC). The abundance of PD-L1 on the tumor cell surface is crucial for the responsiveness of PD-1/PD-L1 immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhijia, Mai, Haixing, Xue, Chunyuan, Fan, Zhongyi, Li, Jiangbo, Chen, Hairui, Huo, Nan, Kang, Xiaofeng, Tang, Chuanhao, Fang, Liaoxin, Zhao, Hui, Han, Yuchen, Sun, Chao, Peng, Huanyan, Du, Yimeng, Yang, Jing, Du, Nan, Xu, Xiaojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693898/
https://www.ncbi.nlm.nih.gov/pubmed/38040417
http://dx.doi.org/10.1136/jitc-2023-007415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693898/
https://www.ncbi.nlm.nih.gov/pubmed/38040417
http://dx.doi.org/10.1136/jitc-2023-007415

Ejemplares similares